Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 4/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | FASN | P49327 | 1/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL361743 | 0.86 | ALDH1A1 (0.45) | MAP4K4DYRK1ATGFBR1LIMK1KDM1A | |
| SCHEMBL28048502 | 0.84 | ALDH1A1 (0.54) | FFAR1DYRK1ARIPK2TGFBR1KDR | |
| SCHEMBL3306715 | 0.83 | CYP11B1 (0.50) | FFAR1MAP4K4DYRK1ARIPK2TGFBR1 | |
| SCHEMBL1850817 | 0.83 | KDM4E (0.42) | FFAR1DYRK1ARIPK2TGFBR1KDM1A | |
| SCHEMBL3301463 | 0.80 | PFKFB3 (0.40) | FFAR1DYRK1ARIPK2TGFBR1KDR | |
| SCHEMBL19435488 | 0.80 | SLC22A12 (0.46) | MAP4K4DYRK1ATGFBR1KDM1AMMP3 | |
| SCHEMBL31070287 | 0.80 | CYP19A1 (0.42) | MAP4K4ALDH1A1HSD17B10 | |
| SCHEMBL3299110 | 0.80 | PIK3CD (0.41) | FFAR1DYRK1ARIPK2TGFBR1KDR | |
| SCHEMBL21625029 | 0.79 | RIPK2 (0.45) | FFAR1DYRK1ARIPK2TGFBR1KDR | |
| SCHEMBL29478085 | 0.79 | RIPK2 (0.60) | FFAR1DYRK1ARIPK2TGFBR1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420052-B2 | Imaging agents useful for identifying AD pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420052-B2 | Imaging agents useful for identifying AD pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420052-B2 | Imaging agents useful for identifying AD pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100098634-A1 | Imaging Agents Useful for Identifying AD Pathology | APP, APBA1, PYGB | FFAR1 2289/4885MAP4K4 4649/4885DYRK1A 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.